Skip to main content
. 2010 Feb 16;28(9):1481–1488. doi: 10.1200/JCO.2009.24.1281

Fig 3.

Fig 3.

Relative change in prostate-specific antigen (PSA) levels at week 12 of therapy in men with castration-resistant prostate cancer treated with abiraterone acetate. Patients who had received prior ketoconazole therapy appear on the left; those who had not received prior ketoconazole appear on the right.